Piper Sandler raised the firm’s price target on Neurocrine (NBIX) to $179 from $175 and keeps an Overweight rating on the shares. The firm notes Neurocrine reported Q3 diluted non-GAAP EPS of $2.17 on revenue of $794.9M, compared to Street estimates of $2.07 and $746.8M, respectively. What was particularly notable was the aggressive ramp of Crenessity, Piper adds.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $164 from $160 at Canaccord
- Neurocrine price target raised to $203 from $175 at Citi
- Neurocrine’s Strong Financial Performance and Growth Potential Justify Buy Rating
- Neurocrine Biosciences Reports Strong Q3 2025 Growth
- Neurocrine’s Strong Q3 Performance and Growth Potential Justify Buy Rating